<DOC>
	<DOCNO>NCT00168103</DOCNO>
	<brief_summary>HAE rare disorder characterize functional C1 esterase inhibitor deficiency . If treat adequately , acute attack HAE life-threatening may even result fatality , especially case swell larynx . This clinical Phase 2/Phase 3 study design provide clinically relevant data dosing , efficacy safety subject HAE .</brief_summary>
	<brief_title>Human C1 Esterase Inhibitor ( C1-INH ) Subjects With Acute Abdominal Facial Hereditary Angioedema ( HAE ) Attacks</brief_title>
	<detailed_description>For subject , single abdominal facial attack treat evaluate . After receive treatment , subject observed minimum 4 hour , could discharge study center report onset symptom relief . Starting 4 hour treatment , subject report insufficient symptom relief could receive second dose double-blind treatment ( call `` rescue medication '' ) follow : C1-INH 20 U/kg bw subject initially receive placebo , C1-INH 10 U/kg bw subject initially receive C1-INH 10 U/kg bw , placebo subject initially receive C1-INH 20 U/kg bw . The study define successful primary outcome measure least one secondary outcome measure meet comparison C1-INH 20 U/kg bw group Placebo group .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Key Documented congenital C1INH deficiency Acute facial abdominal HAE attack Key Acquired angioedema Treatment investigational drug within last 30 day study entry Treatment C1INH concentrate within previous 7 day</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>C1 Inhibitor</keyword>
	<keyword>Hereditary angioedema</keyword>
	<keyword>Acute HAE attack</keyword>
</DOC>